If insurance covers a brand GLP-1 (Wegovy, Zepbound, Ozempic or Mounjaro) at a manageable copay, that route often costs less overall than paying cash.
NexLife is our editor's pick at 94/100 on methodology v4.1. Scores for other providers on this site come from the July 2026 review (six-criterion rubric); v4.1 re-score pending. Last refreshed July 8, 2026.
The decision tree:
- Call insurance member services.
- If covered at meaningful copay: pursue branded.
- If denied: appeal; if the appeal fails, consider cash pay, either a manufacturer self-pay program or compounded medication (not FDA-approved; see cash-pay options).
On Medicare Part D? CMS's Medicare GLP-1 Bridge sets a $50 copay for eligible enrollees from July 1, 2026 to December 31, 2027.
See insurance coverage by carrier.
How we score
Methodology v4.1 weighs pricing transparency (20), total annual cost (20), clinical oversight (15), pharmacy transparency (15), support (10), regulatory disclosure (10) and accessibility (10). NexLife scores 94/100 on v4.1. Scores shown for other providers come from the July 2026 review under the earlier six-criterion rubric; a v4.1 re-score is pending. Full methodology: /methodology.html.